Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell transplant using related or unrelated donor in persons 0-70 years of age diagnosed with dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized by a requirement for red blood cell and platelet transfusions. Three different preparative regimens are included based on disease and donor type.

NCT: NCT02162420

Locations: University of Minnesota Medical Center, Fairview

Link: https://clinicaltrials.gov/ct2/show/NCT02162420?recrs=ad&cond=Dyskeratosis+Congenita&locn=University+of+Minnesota&cntry=US&draw=2&rank=1